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In oncology, there is increasing interest in studying combi-
nations of drugs to improve treatment efficacy and/or
reduce harmful side-effects. Dual-agent Phase I clinical
trials are primarily concerned with drug safety, with the
aim to discover a maximum tolerated combination dose
via dose-escalation; small cohorts of patients are given set
doses of both drugs and monitored to see if any particular
toxic reactions occur. Whether to escalate, de-escalate or
maintain the current dose for either drug for subsequent
cohorts is based on the number and severity of observed
toxic reactions, and a decision rule.
We propose a novel Bayesian phase I trial design for
the study of two chemotherapeutic agents in combination
based on a penalized D-optimality criterion. Patients are
allocated to dose combinations that provide the most
information about the two agents in combination and
their interactive behaviour, subject to a penalty function
that doses patients at combinations with a probability of
toxicity close to some desired target level. Such a criter-
ion compromises between population gain (maximizing
information) and patient gain (treating each patient at a
maximally tolerable combination).
We show how the design can be applied to a dual-agent
Phase I dose-escalation study of Paclitaxel and an Aurora
Kinase Inhibitor in combination. Our simulation studies
show that the method provides accurate and tolerable
recommendations for further clinical testing and has the
ability to outperform other proposed methods.
Published: 29 November 2013
doi:10.1186/1745-6215-14-S1-P41
Cite this article as: Wheeler: A novel Bayesian method for dual-agent
Phase I dose-escalation studies using penalized D-optimality. Trials 2013
14(Suppl 1):P41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
MRC Biostatistics Unit, Cambridge, UK
Wheeler Trials 2013, 14(Suppl 1):P41
http://www.trialsjournal.com/content/14/S1/P41 TRIALS
© 2013 Wheeler; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
